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Available online 20 May 2009Human chorionic gonadotropin (hCG) promotes proliferation of endogenous neural stem
cells, and erythropoietin (EPO) promotes differentiation of these cells into neural stem cells.
The current study examined effects of sequential administration of these two compounds,
initiated 24 h after stroke. At that time, rats were randomized into four treatment groups:
hCG+EPO (3 IM doses hCG over 5 days, followed by 3 IV doses EPO over 3 days), hCG+Saline
using the same schedule, Saline+EPO using the same schedule, or neither drug (Saline+
Saline). The primary endpoint was the composite neurological score, measured 11 times,
from 1 h until 12 weeks post-insult. The neurological score was different across treatment
groups (p<0.03). Pairwise testing of groups found that the hCG+EPO group had significantly
better behavior at 6/10 post-stroke time points as compared to Saline+Saline. The
differences observed when comparing the two-drug group with placebo were less
apparent when comparing either of the one-drug groups with placebo. The two one-drug
treatment arms did not significantly differ at any time point. Treatment with hCG+EPO
significantly reduced total lesion volume by 82–89% compared to the other three treatment
groups. The current therapeutic strategy improved behavioral outcome and reduced lesion
volume with a time window of 24 h after the onset of stroke. The results from these
experiments provide new insight into the effects of these two growth factors on stroke in
rats, and could suggest a potential for translation into human stroke studies.






For most patients with acute ischemic stroke, limited ther-
apeutic options exist beyond 8 h after the onset of stroke. Even
with the acute reperfusion therapies currently available, most
patients who are treated still show significant signs of long-euroscience LSUHSC Neu
.
ayev).
er B.V. All rights reservedterm disability. Consequently, additional therapeutic strate-
gies are needed. One set of therapies that might be of value in
this regard aims to promote repair by administration of
growth factors.
Many growth factors show spontaneously increased levels
in the weeks following stroke (Finklestein et al., 1990). Aroscience Center 2020 Gravier Street, Suite 9B4, Room 946A New
.
Fig. 1 – Improvement in the primary behavioral outcome
measure is shown over time for the four treatment groups.
Animals receiving hCG+EPO, as compared with Saline+
Saline, had significantly lower scores at multiple
timepoints. Data are mean±SEM. *p<0.05, Saline+Saline
vs. hCG+EPO.
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improve the long-term outcome in animal models when
administered the first few days after stroke (Kawamata
et al., 1997; Kawamata et al., 1998; Schneider et al., 2006;
Wang et al., 2004). One mechanism by which growth factors
might influence outcome after stroke is by their actions on
endogenous neural stem cells. Human chorionic gonadotropin
(hCG), like other neurotrophic factors (Craig et al., 1996; Shingo
et al., 2001; Kolb et al., 2007), promotes proliferation of
endogenous neural stem cells. hCG resides in the same
growth factor family as nerve growth factor (Lei and Rao,
2001), crosses the blood brain barrier (Lukacs et al., 1995), and
normally has its receptor present in adult rat brains (Al-Hader
et al., 1997). Erythropoietin (EPO) is a growth hormone (Chen
and Chopp, 2006) that also crosses the blood brain barrier
(Ehrenreich et al., 2002; Kaushansky 2006) and its receptor
mRNA is readily detectable in central nervous system neurons
and glia (Digicaylioglu et al., 1995). EPO also is known to
promote the differentiation of endogenous neural stem cells
into neural stem cells (Shingo et al., 2001).
The current study builds directly on a prior report by Kolb
et al. (2007), who found improved behavioral outcome and
reduced infarct volume with delayed administration of
intraventricular epidermal growth factor followed by EPO
(Kolb et al., 2007) in ratswith experimental stroke.We changed
to hCG+EPO because there is more human experience with
hCG, and both are thought to be endogenous stem cell
mitogens.We decided first to use hCG to promote proliferation
and then use EPO to promote survival and differentiation of
new progenitors. This treatment paradigm (hCG followed by
EPO) was initiated 24 h after experimental stroke, which has
increased human translational potential.2. Results
2.1. Physiological variables
There were no significant differences with respect to rectal
and cranial temperatures between groups. All animals had
reduced body weight during the first week, but regained
weight afterward. There were no significant differences in
body weight between groups at any point during the 12-week
survival period.
2.2. Behavioral findings
Composite Neurological Scores, the primary behavioral end-
point, varied according to treatment. Neurological score was
normal (0) in all animals before MCAo. Contralateral forelimb
placing deficits were clearly present at 60 min after MCAo in
all groups (score, 10–11). Three animals were excluded based
on inadequate ischemia (score, 8–9). The main effect of
treatment was significant (F3,16=4.1, p<0.03), as was main
effect of time (F10,7=23.7, p=0.0002); the time×group interac-
tion across the four treatment groups approached signifi-
cance (p=0.0554, repeated-measures ANOVA, Fig. 1). Post-hoc
comparison of the two-drug treatment group (hCG+EPO) vs.
placebo (Saline–Saline) group found that scores in the two-
drug group were significantly lower (p<0.05, Fisher's pro-tected least-significant difference test), indicating better
neurological status, at 6 of the 10 post-stroke time points:
3 wk, 4 wk, 6 wk, 8 wk, 10 wk, and 12 wk after middle cerebral
artery occlusion (MCAo).
The differences observed when comparing the two-drug
groupwith placeboweremuch less apparent when comparing
either of the one-drug groups with placebo. Thus, when
comparing the neurological scores for Saline+EPO vs. Saline+
Saline, scores in the active treatment group were significantly
lower at only 5/10 timepoints, i.e., at 3 wk, 4 wk, 6 wk, 10 wk,
and 12 wk post-MCAo. Similarly, when comparing the
neurological scores for hCG+Saline vs. Saline+Saline, scores
in the active treatment groupwere again significantly lower at
fewer (7/10) timepoints, i.e., at 2 wk, 3 wk, 4 wk, 6 wk, 8 wk,
10 wk, and 12 wk post-MCAo.
Consistent with the above results, direct comparisons of
the two-drug with the one-drug group favored the former.
Thus, when comparing the composite neurological scores
for hCG+EPO vs. Saline+EPO, scores in the two-drug group
were significantly lower (p<0.05) at 24 h and 4 weeks post-
stroke. At all the other time points, mean scores for hCG+
EPO were always lower than Saline+EPO, but these did not
reach significance. When comparing neurological scores for
hCG+EPO vs. hCG+Saline, scores in the two-drug group were
lower in all but one timepoint, but again these did not
reach significance. The two one-drug treatment arms were
not significantly different at any timepoint.
Regarding the secondary behavioral endpoints, adhesive
test scores also varied according to treatment. The main
effect of treatment was significant (F3,42=2.8, p<0.05), as
was the main effect of time (F7,36=7.3, p<0.0001); the
time×group interaction across the four treatment groups
again approached significance (p<0.08). Post-hoc compar-
ison found that at 3/8 timepoints, all three active treatment
groups showed significantly better adhesive scores as
compared to the Saline+Saline group. Swimming test scores
showed no significance for main effect of treatment group
or for the time×group interaction, though the main effect of
time (F7,33=3.8, p<0.005) was significant. The cylinder test
scores showed no significant main effect of treatment
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trend (p=0.12) toward significance.
2.3. Histopathology
Lesion volume was significantly different across groups
(p<0.03, ANOVA, Fig. 2). Post-hoc testing between groups
disclosed that the lesion volume for hCG+EPO was 82% lower
than the Saline+Saline group (p<0.008), 86% lower than the
Saline+EPOgroup (p<0.004), and89% lower than thehCG+Saline
group (p<0.009). Lesion volume for the Saline+EPO and for the
hCG+Saline groups did not differ significantly from each other,
and neither differed from Saline+Saline. Percent tissue loss
showed very similar trends, but ANOVA did not reach sig-
nificance (hCG+EPO: 12%; hCG+Saline: 42%; Saline+EPO: 35%;
Saline+Saline: 32%).
In threegroups (theSaline+EPO,hCG+Saline, andSaline+Saline
treated animals), microscopic examination of the brain con-
firmed a large extent of cystic necrosis involving neocortex that
extended to subcortical structures. However, in brains from
animals treated with hCG+EPO, frank cystic necrosis in the
neocortex was present in only 2 of 10 animals. In the otherFig. 2 – Panel A: Lesion volume at week 12 in animals with
treatment starting 24 h after stroke. As compared to animals
receiving hCG+EPO, the lesion volume was significantly
smaller (*p<0.01) in animals receiving one (hCG+Saline or
Saline+EPO) or no (Saline+Saline) drug. Data are mean±SEM.
Panel B: The whole brain (top row) and a coronal slice (at
bregma level −1.8 mm) are consistent with these differences
in lesion volume.eight brains, the neocortex was structurally intact but exhibited
subtle to prominent hypercellularity attributable to increases in
microglial nuclei; however, no apparent necrotic or obvious
apoptotic neurons were observed.
Distribution of lesion areas at 12 weeks after MCAo is
presented in Fig. 3. Treatment with hCG+EPO significantly
reduced total lesion areas at two bregma levels compared to
hCG+Saline treated groups.
Seven animals died during the experiment: two rats in the
hCG+EPO group, three rats in the hCG+Saline group, one rat in
Saline+EPO and one rat Saline+Saline groups. All animals died
during one week after surgery.3. Discussion
The current study aimed to evaluate a new treatment
paradigm: use of two sequentially administered growth
factors — one to promote endogenous neural stem cell
proliferation (hCG) and a second to promote differentiation of
these cells into neural stem cells (EPO) (Shingo et al., 2001).
The two-drug regimen, initiated 24 h after the onset of
stroke, showed significant improvement in the primary
behavioral measure and reduction of lesion volume. The
current results achieved these aims in several ways. For
example, the two-drug regimen was superior to the placebo;
note that this was true more often than either one-drug
group being superior to the placebo. Also, lesion volume was
substantially reduced with the two-drug regimen, but not
with either one-drug regimen.
Brain repair represents a potential avenue to reduce
disability after stroke with treatments initiated beyond the
current eight-hour time window (Cramer, 2008). A number of
therapeutic approaches have been advanced. One of them is
EPO, a hematopoietic growth hormone, which regulates
survival, proliferation and differentiation of erythroid pro-
genitor cells (Shingo et al., 2001). In preclinical studies,
treatment with EPO at 24 h after onset of stroke significantly
improved functional outcome (Wang et al., 2004). Although
EPO seems to be potentially safe at the neuroprotective-
proven doses, cardiovascular or cerebrovascular events can
occur as a result of its bonemarrow stimulating activities. EPO
therapies for anemia or cerebrovascular diseases require
frequent injections or high-dose systemic administration
that may cause unwanted side effects. Hypertension, throm-
bosis and increased hematocrit are common side effects of
EPO (Chen and Chopp, 2006). High dose EPO (5,000–10,000 U/kg)
is necessary for achieving neuroprotection in focal cerebral
ischemia in rats (Chang et al., 2008).
Kolb et al. (2007) found that, in a rat model of stroke,
sequential intraventricular administration of epidermal
growth factor, followed by erythropoietin, promoted improved
behavioral status as well as regeneration of damaged neocor-
tex. These effects were seen with their two-drug regimen, but
not with administration of only one of their two growth
factors. Favorable effects were seen even when growth factor
administration was delayed for up to seven days after stroke.
The study by Kolb et al. (2007) used intraventricular drug
administration, which is challenging in human subjects, and
Fig. 3 – Distribution of lesion areas at 12 weeks after MCAo, shown for seven rostrocaudal forebrain coronal levels in all groups.
Treatment with hCG+EPO significantly reduced total lesion areas at two bregma levels compared to hCG+Saline treated groups.
Values are mean±SEM, *p<0.05, hCG+EPO vs. hCG+Saline.
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limited experience in human studies.
The current study aimed to replicate the findings of Kolb
et al. (2007), but with two important changes geared toward
promoting human translational application: using the IV/IM
route instead of intraventricular, and replacing epidermal
growth factor with a mitogen (hCG), which has a long history
of safety in human subjects. In addition, a reduced dose of EPO
(1400 U/kg per day during 3 days) was chosen to avoid
unwanted side effects.
Poststroke recovery treatments are likely to enhance
structural and functional reorganization (i.e. plasticity) of
the damaged brain. Recent studies suggest that neurores-
torative events, such as neurogenesis, angiogenesis, and
synaptic plasticity, contribute to functional improvement
after stroke (Chen and Chopp, 2006). Here we report that
administration of hCG and EPO, together but not alone,
stimulate tissue re-growth and recovery of motor function
after transient MCAo. The improvement of behavioral score
became evident only three weeks after ischemic insult and
persisted throughout the 12-week survival period. Also this
motor recovery was greater than that seen by any previous
treatments on animals with similar functional loss (Kolb
et al., 2007.
This study does not clarify the mechanism of this
significant and substantial recovery. However, we speculate
that several factors might contribute to the observations in
this study. In terms of the progression of the injury,
neuroprotective strategies are usually administered within
hours of the time of injury in order to protect the ischemic core
and progressive loss of neurological cells within the penum-
bra. Alternately, neuro-regeneration strategies should, in
theory, have a much greater time window in which to
administer therapeutics, ranging from hours to weeks. Thetiming of the hCG and EPO effect of the regimen would argue
in favor of the latter strategy: neuro-regeneration. However,
although these compounds are administered for their primary
neurogenic properties, hCG and EPO have well-described
secondary pharmacologic effects that may contribute to
improved structural and functional recovery, including angio-
genic, anti-apoptotic, and anti-inflammatory actions, and
perhaps even effects on brain plasticity.
There were several weaknesses apparent in the current
study. Some of the secondary behavioral endpoints did not
show the same effect of the treatment group that the primary
behavioral endpoint did, possibly due to limited study power.
Histological methods did not permit the same level of insight
into the mechanism of treatment effect as compared to Kolb
et al. (2007). Future studies will examine this issue in greater
detail. In addition, we did not measure blood gases and
plasma glucose in order to avoid the cannulation of the
femoral artery, which often causes a hind limb ischemia and
would be a problem in conducting four different behavioral
tests. To control physiological parameters, the rats were orally
intubated, immobilized with pancuronium bromide, and
mechanically ventilated to avoid hypoxia. Rectal and cranial
temperatures were monitored and held at normothermic
levels throughout the experiment. One strength of the current
study is that many experimental method details, such as
timing and route of drug administration plus choice of
medications, lay the groundwork for direct translation to
human subjects with stroke (Clinicaltrials.gov identifier:
NCT00362414). Another strength is the excellent safety record
of hCG. Also, while safety of erythropoiesis stimulating agents
has come under review, it should be noted that administration
of EPO only during three days, and at submaximal doses, has
generated a high level of confidence in the potential safety of
the current approach.
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Brain repair has the potential to improve the outcome in
stroke patients. The current study found that both a two-
drug and a one-drug approach, initiated 24 h after onset of
experimental stroke in rats, improved behavioral outcome.
The two-drug approach showed some advantages, particu-
larly with respect to lesion volume. A clinical trial examin-
ing the safety of this approach in human subjects with
stroke has been initiated (Clinicaltrials.gov identifier:
NCT00362414).5. Experimental procedures
5.1. Protocols and animal care
Experimental protocols were approved by the Inotek's
Animal Care and Use Committee, Lexington, MA. Male Long
Evans rats (280–330 g; Charles River Laboratories, Wilming-
ton, MA) were fasted overnight but allowed free access to
water. Following atropine sulfate (0.5 mg/kg, i.p.), anesthesia
was induced with 3.5% halothane in a mixture of 70% nitrous
oxide and a balance of oxygen. Rats were orally intubated,
immobilized with pancuronium bromide (0.6 mg/kg, IV), and
mechanically ventilated. Rectal (CMA/150 Temperature Con-
troller, CMA/Microdialysis AB, Stockholm, Sweden) and
cranial (left temporalis muscle) (Omega Engineering, Stam-
ford, CT) temperatures were monitored and maintained at
36.0±0.5 °C during surgical procedure. The right femoral vein
was catheterized for drug infusion. During the 12-week
survival period, rectal temperature and body weight were
monitored periodically.
5.2. Middle cerebral artery occlusion
The right middle cerebral artery (MCA) was occluded for
90 min by a modification (Belayev et al., 1996) of the
intraluminal-suture occlusion method (Longa et al., 1989). In
brief, the right common carotid artery (CCA) was exposed
through a midline neck incision and dissected free of
surrounding nerves. The occipital branches of the external
carotid artery (ECA) were coagulated, and the pterygopalatine
artery was ligated. A 4-cm length of 3-0 monofilament nylon
suture was then inserted via the proximal ECA into the
internal carotid artery (ICA) and MCA, a distance of 20–22 mm
from the CCA bifurcation according to the animal's weight,
thereby occluding the MCA. Prior to use, the tip of the suture
was heat-blunted, and a 22-mm distal segment of the suture
was coated with poly-L-lysine solution (0.1% [wt/vol]) and
dried at 60 °C for 1 h; this coating procedure enhances the
reproducibility of the resulting infarct (Belayev et al., 1996).
After suture placement, the neck incision was closed, and
animals were allowed to awaken from anesthesia. At 60 min
following MCA occlusion (MCAo), animals were tested on a
standardized neurobehavioral battery to confirm the presence
of a neurological deficit (Belayev et al., 1996). After 90 min of
MCAo, rats were reanesthetized, temperature probes were
reinserted, and the intraluminal suturewas carefully removed.After surgery rats were observed carefully for signs of
discomfort; no such signs were observed. Animals were
housed in individual cages.
5.3. Behavioral assessments
The primary behavioral endpoint was the Composite Neuro-
logical Score (0–12 points, 0=normal and 12=maximal deficit)
(Belayev et al., 1996), a battery that consists of two tests that
have been used previously to evaluate various aspects of
neurologic function: (1) the postural reflex test, developed by
Bederson et al. (1986) to examine upper body posture while the
animal is suspended by the tail; and (2) the forelimb placing
test, developed by De Ryck et al. (1989) to examine sensor-
imotor integration in forelimb placing responses to visual,
tactile and proprioceptive stimuli. Tests were conducted by an
observer blinded to the treatment group. The composite
neurological score was tested 1 h into the MCAo, then again
at 24 h, 48 h, 1 wk, 2 wk, 3 wk, 4 wk, 6 wk, 8 wk, 10 wk, and
12 wk post-MCAo. The severity of stroke injury was assessed
by behavioral examination of each rat at 60 min after onset of
MCAo. Rats that did not demonstrate high-grade contralateral
deficit (score, 10–11) were excluded from further study. Three
secondary behavioral endpoints were also measured, each
eight times after stroke, starting at week 1, 2, 3, 4, 6, 8, 10, and
12 post-MCAo. These endpoints were as follows: (1) adhesive
test (Schallert et al., 2003), which measures sensory function
during 2 min, with four trials per day, and each trial separated
by at least 5 min; (2) forepaw inhibition (swimming) test
(Gonzalez et al., 2003), which is an indicator of forelimb
impairment. Scoring of forelimb inhibition is done by counting
the numbers of strokes made by each forelimb, and reported
as (strokes made with impaired limb)− (strokes made with
nonimpaired limb) (five trials were performed per day); (3)
cylinder test (Jones et al., 2003), whichmeasures abnormalities
of forelimb postural-motor behavior. The forelimb asymmetry
score was calculated using the formula: (total ipsilateral limb
use+1/2 bilateral) / total limb use×100. Each animal was
videotaped for 5 min.
5.4. Treatment and experimental groups
The two active drugs were human chorionic gonadotropin
(hCG, Harbor-UCLA Research and Education Institute, Tor-
rance, CA), given as 440 IU/day, IM, on days 1, 3, and 5; and
erythropoietin (EPO, Epogen, Henry Schein, Melville, NY),
given as 1440 IU/day, IV, by an osmotic pump (Alzet 2ML1;
Cupertino, CA) into the right femoral vein, on days 6, 7, and 8
after MCAo. In the current study, hCG was used as a mitogen
for endogenous neural stem cells for two reasons. First, our
data (unpublished observations) found hCG to be an effective
mitogen. Second,most of the factors identified in prior studies
as having endogenous neural stem cells mitogen activity have
limited clinical experience in humans, while hCG is known to
have an excellent safety profile.
At 24 h after MCAo, the animals were randomly assigned to
one of four treatment groups: Group A (hCG+EPO, n=13), Group
B (hCG+Saline, n=15), Group C (Saline+EPO, n=12) and Group D
(Saline+Saline, n=13). The treatment schedule and methods
were identical across the four groups.
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Following a 12-week survival period, animals were deeply
anesthetized with halothane and perfused transcardially with
isotonic saline followed by a perfusion with paraformalde-
hyde (4% in phosphate buffer). Brains were then removed and
brain blocks were embedded in paraffin. Twelve-micron-thick
sections were cut in the coronal plane and stained with
hematoxylin and eosin. Lesion volume and percent normal
tissue loss were quantitated by digitizing histological sections
(MCID™ Core imaging software, InterFocus Imaging Ltd,
Linton, Cambridge, UK) at 7 standardized coronal levels
(bregma levels: +2.7, +1.2, −0.3, −1.3,−1.8, −3.8 and −5.0 mm)
(Konig and Klippel, 1963). An investigator blinded to the
experimental groups outlined the areas of the lesion, which
were clearly demarcated; the ventricles, as well as the left and
right hemisphere, were contoured at each level. The following
analysis was conducted: (A) Lesion volume was calculated as
the product of the cross-sectional area for all sections, and the
distance between the sections was determined using Simp-
son's method (Carnevale 1986). (B) Residual (normal) tissue in
the right hemisphere (mm3) was calculated applying the
following formula: (right hemisphere volume−right ventricle
− lesion volume). (C) Tissue loss was calculated as a difference
in the amount of histologically-intact residual tissue between
the lesioned and the unlesioned hemispheres. (D) Percent
[relative to unlesioned (left) hemisphere volume] was calcu-
lated applying the following formula: (Tissue loss×100/
Residual tissue in left hemisphere).
5.6. Statistical analysis
Data were presented as mean values±SEM. Neurobehavioral
scores and infarct size data were analyzed by repeated-
measures analysis of variance (ANOVA) with post hoc tests.
Physiological variables were compared using Student t tests.
Differences at p<0.05 were considered statistically significant.Acknowledgments
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